ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.

Abstract excerpt

Relapse following targeted therapy remains a central challenge in oncogene-driven cancers. Drug-tolerant persister cells that survive initial treatment without genetic resistance seed relapse, yet despite over a decade of research, no persister-directed therapy has reached clinical approval. To bridge this gap, we developed ResMap, a community resource providing both a standardized experimental framework and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Cell Line, Tumor